Pembrolizumab has also been approved for the treatment of PD-L1-positive non-small cell lung cancer in the US (2015) and Japan (2016), in addition to the treatment of Hodgkin lymphoma and urothelial carcinoma. Here, CD274 is linked to non-small cell lung carcinoma.